These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 38849011

  • 1. Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.
    Oluwalana D, Adeleye KL, Krutilina RI, Chen H, Playa H, Deng S, Parke DN, Abernathy J, Middleton L, Cullom A, Thalluri B, Ma D, Meibohm B, Miller DD, Seagroves TN, Li W.
    Cancer Lett; 2024 Aug 10; 597():217011. PubMed ID: 38849011
    [Abstract] [Full Text] [Related]

  • 2. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
    Deng S, Krutilina RI, Wang Q, Lin Z, Parke DN, Playa HC, Chen H, Miller DD, Seagroves TN, Li W.
    Mol Cancer Ther; 2020 Feb 10; 19(2):348-363. PubMed ID: 31645441
    [Abstract] [Full Text] [Related]

  • 3. Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents.
    Chen H, Deng S, Albadari N, Yun MK, Zhang S, Li Y, Ma D, Parke DN, Yang L, Seagroves TN, White SW, Miller DD, Li W.
    J Med Chem; 2021 Aug 26; 64(16):12049-12074. PubMed ID: 34378386
    [Abstract] [Full Text] [Related]

  • 4. Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer.
    Deng S, Krutilina RI, Hartman KL, Chen H, Parke DN, Wang R, Mahmud F, Ma D, Lukka PB, Meibohm B, Seagroves TN, Miller DD, Li W.
    Mol Cancer Ther; 2022 Jul 05; 21(7):1103-1114. PubMed ID: 35499388
    [Abstract] [Full Text] [Related]

  • 5. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
    Mahmud F, Deng S, Chen H, Miller DD, Li W.
    Cancer Lett; 2020 Dec 28; 495():76-88. PubMed ID: 32920198
    [Abstract] [Full Text] [Related]

  • 6. Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis.
    Krutilina RI, Hartman KL, Oluwalana D, Playa HC, Parke DN, Chen H, Miller DD, Li W, Seagroves TN.
    Cancers (Basel); 2022 Oct 29; 14(21):. PubMed ID: 36358755
    [Abstract] [Full Text] [Related]

  • 7. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
    Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, Loberg R, Friberg G, Kendall RL, Saffran D, Radinsky R.
    Mol Cancer Ther; 2013 Nov 29; 12(11):2356-66. PubMed ID: 23990115
    [Abstract] [Full Text] [Related]

  • 8. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
    Deng S, Banerjee S, Chen H, Pochampally S, Wang Y, Yun MK, White SW, Parmar K, Meibohm B, Hartman KL, Wu Z, Miller DD, Li W.
    Cancer Lett; 2023 Feb 28; 555():216046. PubMed ID: 36596380
    [Abstract] [Full Text] [Related]

  • 9. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE, Wang Y, Hwang DJ, Xue Y, Costello T, Hamilton D, Chen Q, Yang J, Park F, Dalton JT, Miller DD, Li W.
    Cancer Res; 2018 Jan 01; 78(1):265-277. PubMed ID: 29180476
    [Abstract] [Full Text] [Related]

  • 10. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, Carrier L, Bu Y, Hangauer D, Rowan BG.
    Mol Cancer Ther; 2012 Sep 01; 11(9):1936-47. PubMed ID: 22784709
    [Abstract] [Full Text] [Related]

  • 11. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE, Gilbert SF, Gril B, Narwal R, Peacock Brooks DL, Tice DA, Steeg PS, Lipkowitz S.
    Breast Cancer Res; 2019 Feb 18; 21(1):27. PubMed ID: 30777098
    [Abstract] [Full Text] [Related]

  • 12. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J.
    Br J Cancer; 2014 Mar 18; 110(6):1497-505. PubMed ID: 24569463
    [Abstract] [Full Text] [Related]

  • 13. VERU-111, an Orally Available Tubulin Inhibitor, Suppresses Ovarian Tumor Growth and Metastasis.
    Waddell S, Zhao G, Liu Z, Chen H, Zhang W, Wang Y, Miller DD, Yue J, Li W.
    J Pharmacol Exp Ther; 2024 Jun 27. PubMed ID: 38936977
    [Abstract] [Full Text] [Related]

  • 14. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T.
    Cancer Lett; 2017 May 28; 394():52-64. PubMed ID: 28254410
    [Abstract] [Full Text] [Related]

  • 15. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
    Boichuk S, Galembikova A, Syuzov K, Dunaev P, Bikinieva F, Aukhadieva A, Zykova S, Igidov N, Gankova K, Novikova M, Kopnin P.
    Molecules; 2021 Sep 24; 26(19):. PubMed ID: 34641324
    [Abstract] [Full Text] [Related]

  • 16. G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly.
    Lv X, He C, Huang C, Hua G, Wang Z, Remmenga SW, Rodabough KJ, Karpf AR, Dong J, Davis JS, Wang C.
    Mol Cancer Ther; 2017 Jun 24; 16(6):1080-1091. PubMed ID: 28258163
    [Abstract] [Full Text] [Related]

  • 17. Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
    Chen H, Deng S, Wang Y, Albadari N, Kumar G, Ma D, Li W, White SW, Miller DD, Li W.
    J Med Chem; 2020 Jan 23; 63(2):827-846. PubMed ID: 31860298
    [Abstract] [Full Text] [Related]

  • 18. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K, Le A, Weaver VM, Werb Z.
    Oncotarget; 2016 Dec 13; 7(50):82889-82901. PubMed ID: 27756881
    [Abstract] [Full Text] [Related]

  • 19. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T, Lin S, Ji M, Xue N, Liu Y, Zhang Z, Zhang K, Zhang J, Zhang Y, Wang Q, Sheng L, Li Y, Lu D, Chen X, Xu H.
    Cancer Lett; 2020 Dec 28; 495():22-32. PubMed ID: 32931884
    [Abstract] [Full Text] [Related]

  • 20. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.
    Mol Pharmacol; 2019 Jul 28; 96(1):73-89. PubMed ID: 31043459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.